H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson's disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson's disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. Lundbeck A/S has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients living with serious neurological conditions. The company was founded in 1915 and is headquartered in Valby, Denmark.…
H. Lundbeck AS (HLUBF) (Q3 2026) Earnings Call Highlights: Raised Guidance and Strong Vyepti ...
H. Lundbeck (CPH: HLUN-A) is listed on Nasdaq Copenhagen, where its shares trade in DKK. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 5,000 employees.
The shares were at 58.70 DKK on 20 November 2026, up 74.5% over 52 weeks. Its 52-week range is 31.40 DKK to 62.00 DKK: the price is 5.3% below the high and 86.9% above the low.
At a market capitalisation of 58.24B DKK, it trades at 14.4 times trailing earnings. The median trailing P/E of its 16 largest Drug Manufacturers - Specialty & Generic peers is 29.8, a discount of 52% for HLUN-A. It pays a dividend yielding 1.95% (it pays out 28% of its earnings), against a median of 2.13% among the dividend payers in that peer group.
H. Lundbeck reports return on equity of 12.8%, an operating margin of 24.4% and revenue up 5.2% year over year.
Its debt exceeds its cash by 4.98B DKK, a debt-to-equity ratio of 0.47. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. The next earnings report is expected on 10 February 2027.